These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 12110999

  • 1. Methodological problems with ecstasy and the SCL-90.
    Cole JC, Sumnall HR, Wagstaff GF.
    Psychopharmacology (Berl); 2002 Jul; 162(2):215-7; discussion 218-22. PubMed ID: 12110999
    [No Abstract] [Full Text] [Related]

  • 2. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J, Fadón P, Mata F, Rubio G, Santo-Domingo J.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998 Jul; 26(4):260-3. PubMed ID: 9807860
    [Abstract] [Full Text] [Related]

  • 3. [Hallucinogen induced psychic disorders. Subjective experiences, psychopathology and differential diagnosis].
    Hermle L, Gouzoulis-Mayfrank E, Spitzer M.
    Fortschr Neurol Psychiatr; 1996 Dec; 64(12):482-91. PubMed ID: 9053389
    [Abstract] [Full Text] [Related]

  • 4. [Effects of ecstasy on the body].
    Saarijärvi S, Lopperi M.
    Duodecim; 2003 Dec; 119(13):1211-5. PubMed ID: 12908183
    [No Abstract] [Full Text] [Related]

  • 5. [Medication-induced psychoses].
    Senon JL, Lafay N, Padet N.
    Encephale; 2003 Sep; 29(Pt 2):S8-11. PubMed ID: 14710528
    [No Abstract] [Full Text] [Related]

  • 6. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.
    Kouimtsidis C, Schifano F, Sharp T, Ford L, Robinson J, Magee C.
    Psychosomatics; 2006 Sep; 47(1):86-7. PubMed ID: 16384814
    [No Abstract] [Full Text] [Related]

  • 7. [The dangers of "ecstasy"].
    Gouzoulis-Mayfrank E, Hermle L.
    Nervenarzt; 1994 Sep; 65(9):648-50. PubMed ID: 7991015
    [No Abstract] [Full Text] [Related]

  • 8. [Psychiatric and cognitive long-term effects of ecstasy].
    Høiseth G, Løvåsdal Ø, Titze TK, Bramness JG, Bachs L.
    Tidsskr Nor Laegeforen; 2006 Feb 23; 126(5):596-8. PubMed ID: 16505868
    [Abstract] [Full Text] [Related]

  • 9. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E, Daumann J.
    Addiction; 2006 Mar 23; 101(3):348-61. PubMed ID: 16499508
    [Abstract] [Full Text] [Related]

  • 10. [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].
    Nielsen JC, Nicholson K, Pitzner-Jørgensen BL, Undén M.
    Ugeskr Laeger; 1995 Feb 06; 157(6):724-7. PubMed ID: 7701630
    [Abstract] [Full Text] [Related]

  • 11. Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
    Alati R, Kinner SA, Hayatbakhsh MR, Mamun AA, Najman JM, Williams GM.
    Drug Alcohol Depend; 2008 Jan 01; 92(1-3):108-15. PubMed ID: 17850992
    [Abstract] [Full Text] [Related]

  • 12. MDMA (Ecstasy) use and psychiatric problems.
    Guillot CR, Berman ME.
    Psychopharmacology (Berl); 2007 Jan 01; 189(4):575-6. PubMed ID: 17061108
    [No Abstract] [Full Text] [Related]

  • 13. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS.
    Biol Psychiatry; 1996 May 01; 39(9):819-20. PubMed ID: 8731525
    [No Abstract] [Full Text] [Related]

  • 14. The BDI of the beholder.
    Cole JC, Sumnall HR.
    J Psychopharmacol; 2002 Mar 01; 16(1):103. PubMed ID: 11949766
    [No Abstract] [Full Text] [Related]

  • 15. [On ecstasy].
    Boulu R.
    Ann Pharm Fr; 2003 May 01; 61(3):155-6. PubMed ID: 12714927
    [No Abstract] [Full Text] [Related]

  • 16. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN, Spigset O, Slørdal L.
    Basic Clin Pharmacol Toxicol; 2008 Jan 01; 102(1):15-24. PubMed ID: 18047478
    [Abstract] [Full Text] [Related]

  • 17. [Toxicity of ecstasy].
    Mas M, Farré M, Roset PN, Camí J.
    Med Clin (Barc); 1998 Oct 24; 111(13):516-7. PubMed ID: 9859071
    [No Abstract] [Full Text] [Related]

  • 18. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Sass H.
    Fortschr Neurol Psychiatr; 1999 Dec 24; 67(12):574-6. PubMed ID: 10683753
    [No Abstract] [Full Text] [Related]

  • 19. [New Drugs: Ectasy and Gamma-Hydroxy-Butyrate (GHB)].
    Feldman N, Croquette-Krokar M.
    Vertex; 2002 Dec 24; 13(47):5-8. PubMed ID: 11967570
    [Abstract] [Full Text] [Related]

  • 20. [Ecstasy: idiosyncrasy, overdosage or collateral effects].
    Avila de Tomás JF.
    Med Clin (Barc); 1998 Oct 24; 111(13):517-8. PubMed ID: 9859072
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.